Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study

por Romanowski, Barbara, Schwarz, Tino F, Ferguson, Linda M, Peters, Klaus, Dionne, Marc, Schulze, Karin, Ramjattan, Brian, Hillemanns, Peter, Catteau, Grégory, Dobbelaere, Kurt, Schuind, Anne, Descamps, Dominique
Publicado em 2011

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study

por Romanowski, Barbara, Schwarz, Tino F, Ferguson, Linda M, Ferguson, Murdo, Peters, Klaus, Dionne, Marc, Schulze, Karin, Ramjattan, Brian, Hillemanns, Peter, Behre, Ulrich, Suryakiran, Pemmaraju, Thomas, Florence, Struyf, Frank
Publicado no Hum Vaccin Immunother (2014)